Kratom products frequently mislabeled and increasingly potent, studies find

Researchers at the University of Florida have found that many commercially available kratom products are frequently mislabeled, with chemical compositions that differ from their packaging. The study, published in Drug Testing and Analysis, highlights a lack of transparency in a rapidly expanding marketplace where products are often sold as generic kratom despite being chemically and pharmacologically distinct from the traditional Mitragyna speciosa leaf.

Concerns are growing regarding the rise of 7-hydroxymitragynine (7-OH), a potent synthetic derivative often marketed under the kratom label. While traditional kratom contains various alkaloids, 7-OH products are chemically enriched or semi-synthetic and can exceed the potency of morphine. Medical professionals have noted that these products bear little resemblance to traditional kratom tea or leaf.

This shift in product composition has led to significant health implications. Poison centers in the United States have reported a 67.8 percent increase in kratom or 7-OH poisoning symptoms over the past year. Additionally, medical reports have documented acute withdrawal symptoms in users attempting to quit high-dose 7-OH products, underscoring the need for stronger manufacturing standards and more transparent labeling.